Phase II study of Xyotax [paclitaxel poliglumex] in advanced hormone refractory prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2016
At a glance
- Drugs Paclitaxel poliglumex (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Aug 2008 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 24 Aug 2008 Actual patient number (29) added as reported by ClinicalTrials.gov.